Corcept Concludes Patient Recruitment in the P-II Study of Dazucorilant for Amyotrophic Lateral Sclerosis (ALS)
Shots:
- The company has achieved the target patient recruitment (n=249) across the EU, the US & Canada in the P-II (DAZALS) study investigating dazucorilant (150mg & 300mg, daily) vs PBO for 24wks.
- The 1EP of the study includes the change in ALSFRS-R to assess the motor impairment & functional decline in ALS patients from baseline and 2EPs are the OS as well as QoL. The company anticipates the clinical data by the end of 2024
- Dazucorilant, a cortisol modulator, selectively binds to the glucocorticoid receptor (GR) that is currently under evaluation for ALS and has potential for various neurologic disorders
Ref: Corcept Therapeutics | Image: Corcept Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
